- Home
- FRHC vs LEGN Comparison
FRHC vs LEGN Comparison
Compare FRHC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRHC
- LEGN
- Stock Information
- Founded
- FRHC 1981
- LEGN 2014
- Country
- FRHC United States
- LEGN United States
- Employees
- FRHC N/A
- LEGN N/A
- Industry
- FRHC Investment Bankers/Brokers/Service
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FRHC Finance
- LEGN Health Care
- Exchange
- FRHC Nasdaq
- LEGN Nasdaq
- Market Cap
- FRHC 7.8B
- LEGN 7.0B
- IPO Year
- FRHC N/A
- LEGN 2020
- Fundamental
- Price
- FRHC $170.25
- LEGN $27.69
- Analyst Decision
- FRHC
- LEGN Strong Buy
- Analyst Count
- FRHC 0
- LEGN 13
- Target Price
- FRHC N/A
- LEGN $75.67
- AVG Volume (30 Days)
- FRHC 74.7K
- LEGN 1.5M
- Earning Date
- FRHC 06-13-2025
- LEGN 05-13-2025
- Dividend Yield
- FRHC N/A
- LEGN N/A
- EPS Growth
- FRHC N/A
- LEGN N/A
- EPS
- FRHC 5.36
- LEGN N/A
- Revenue
- FRHC $1,578,152,000.00
- LEGN $728,303,000.00
- Revenue This Year
- FRHC N/A
- LEGN $65.96
- Revenue Next Year
- FRHC N/A
- LEGN $52.55
- P/E Ratio
- FRHC $31.62
- LEGN N/A
- Revenue Growth
- FRHC 79.07
- LEGN 112.46
- 52 Week Low
- FRHC $68.82
- LEGN $29.27
- 52 Week High
- FRHC $164.83
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- FRHC 78.21
- LEGN 29.04
- Support Level
- FRHC $138.99
- LEGN $30.25
- Resistance Level
- FRHC $157.99
- LEGN $33.30
- Average True Range (ATR)
- FRHC 4.50
- LEGN 1.78
- MACD
- FRHC 2.55
- LEGN -0.53
- Stochastic Oscillator
- FRHC 93.42
- LEGN 3.10
About FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.